SCHOTT Pharma Announces Major Expansion in the U.S. with a New Syringe Manufacturing Facility

SCHOTT Pharma has disclosed plans to establish a new manufacturing facility in Wilson, North Carolina, marking a significant expansion in the United States. The initiative represents a $371 million investment, projected to create over 400 jobs in the region. This strategic move aligns with SCHOTT Group’s ambition to enhance its U.S. presence and meet the growing demand for prefillable glass and polymer syringes, essential for delivering mRNA, GLP-1, and other therapies.

The upcoming plant is set to be the first of its kind in the U.S., focusing on the production of prefillable polymer syringes crucial for mRNA medication storage and glass syringes for GLP-1 therapies. Scheduled for groundbreaking by the end of 2024, the facility is expected to commence operations in 2027, adding 401 jobs and vastly strengthening the domestic supply chain for critical medical syringes.

Andreas Reisse, CEO of SCHOTT Pharma, emphasized the facility's role in promptly fulfilling U.S. orders for biologic therapies that demand specific drug stability and storage conditions, thus fostering a more resilient and efficient pharmaceutical industry supply chain. The location in Wilson, chosen for its proximity to the Research Triangle and a robust pool of talent, represents a strategic step towards addressing the escalating demand for SCHOTT Pharma’s high-value solutions in the U.S. market.

Supported by state and local incentives, and anticipated to generate high-wage employment, this development underscores North Carolina's commitment to fostering growth in the biopharmaceutical sector. SCHOTT Pharma’s expansion into Wilson is not only a testament to the area's potential for biotech innovation but also marks a significant investment in enhancing global healthcare infrastructure.